This report provides detailed analysis of worldwide markets for Insulin Pen from 2011-2016, and provides extensive market forecasts (2016-2021) by region/country and subsectors. It covers the key technological and market trends in the Insulin Pen market and further lays out an analysis of the factors influencing the supply/demand for Insulin Pen, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
An insulin pen is used to inject insulin for the treatment of diabetes. Insulin is a hormone produced by the pancreas. It is composed of an insulin cartridge (integrated or bought separately) and a dial to measure the dose, and is used with disposable pen needles to deliver the dose. It was introduced and marketed as Novopen by the Danish company Novo Nordisk in 1985. Insulin pen devices are designed to provide a convenient and easy means of insulin administration for the patient and can be divided into 2 categories: the reusable, durable pen, and the disposable, prefilled pen. These insulin pen devices are an alternative to the traditional insulin vial-and-syringe method and offer many advantages. Insulin pens have also been found to be less painful than the vial-and-syringe method and are often associated with greater patient preference and social acceptability. As a result, this method of insulin delivery may ultimately help to improve glycemic control and should be considered when prescribing insulin products.
GCC's report, Global Insulin Pen Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Insulin Pen market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Insulin Pen market areNovo Nordisk (Denmark), Eli Lilly (USA), Sanofi (France), Owen Mumford (UK), Bioton (Poland), Wockhardt (India), Tonghua Dongbao (China), United Laboratories (China), Beijing Gangan (China), Delfu (China).
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Insulin Pen industry has been provided.